Nasdaq · Biotech stocks database
FHTX (Foghorn Therapeutics Inc.) stock: $1.87, $111.1M market cap, $167.6M cash, -$56.5M EV, $161.2M fully diluted market cap. Lead program: FHD-286 (Advanced Hematologic Malignancy; Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia), Phase 1. Data from Fully Diluted's biotech stocks database.
Our proprietary Gene Traffic Control ® platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within this system. We have developed unique capabilities that have yielded new insights and scalability in drugging this new, previously untapped and promising area.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $167.6M |
|---|---|
| Debt | $0.0M |
| Net cash | $167.6M |
| Enterprise value | -$56.5M |
| Basic shares | 59.4M shares |
| Fully diluted shares | 86.2M shares |
| Fully diluted market cap | $161.2M |
| Cash per share | $2.82 |
| Quarterly burn | $17.8M |
| Cash runway | 9.4 quarters |
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Cap table as of 2026-06-30.
Loading FHTX daily closes…